Endometrial Ablation Devices Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2024 – 2032

Endometrial Ablation Devices Market Size

Endometrial Ablation Devices Market size is projected to amass considerable returns between 2024-2032, on account of the myriad benefits of uterine ablation procedures, such as reduced risks of uterine infection and faster recovery. The demand for these devices is surging amongst the female population owing to the irregular blood flow in between the menstrual cycles. As per Endometriosis UK statistics, approximately 10% of the global female population suffer from the condition.
 

In addition, the rapid advancements in minimally invasive surgical techniques and the rising burden of gynecological disorders including cervical cancer and hormone disorders like polycystic ovary syndrome (PCOS) will also impel the adoption of endometrial ablation procedures in the upcoming years. According to the CDC estimates, PCOS affects nearly 6% to 12% of the American women of reproductive age, and is one of the leading causes of infertility.
 

The growing emphasis on boosting awareness of gynecological cancer, along with the growing incidence of adenomyosis in women, particularly after 50 years of age.
 

Despite these favorable growth environments, the risks and complications associated with uterine ablation surgery such as uterine perforation, shortness of breath, and high fever may create a hindrance to the market development to a certain extent.
 

Endometrial Ablation Devices Market Trends

The constant technological innovations in endometrial ablation devices to support quick patient response and recovery would potentially support the industry outlook. This would enable companies to build on the innovation and introduce novel products. For instance, in 2023, Hologic Inc. announced approval of NovaSure V5 endometrial ablation device in European and Canadian markets. The device incorporates improved features and an updated cervical seal, with EndoForm technology designed to accommodate a range of cervical canals and increase the sealing surface.
 

Endometrial Ablation Devices Market Analysis

Cryoablation technology segment is anticipated to hold a considerable share by 2032. The segmental growth can be credited to the high safety and less-invasive nature of the cryoablation procedure as compared to surgery. Fewer side effects, cost-effectiveness, and less damage to surrounding tissues are favoring the popularity of technology over the coming years.
 

The ambulatory surgical centers segment would accrue profitable gains over the next ten years. Potential benefits offered by ASCs including lower cost of care, reduced time, increase safety, superior convenience and affordability, and predictable scheduling are encouraging the patients to opt for these healthcare facilities, pushing the demand for endometrial ablation devices.  
 

Europe endometrial ablation devices market will register appreciable value by 2032, considering the robust healthcare system in countries including Germany, especially with regards to hospital beds, trained staff, and infrastructure. Additionally, the escalating healthcare expenditure and the high prevalence of cervical cancer in countries like the UK and France, are expected to fuel the regional industry outlook in the years ahead.
 

Endometrial Ablation Devices Market Share

The competitive landscape of the endometrial ablation devices industry consists of companies such as:

•  AngioDynamics
•  Medtronic
• Boston Scientific Corporation
• Richard Wolf GmbH
• Karl Storz GmbH & Co. KG
• Hologic Inc.
• Smith & Nephew
• The Cooper Companies Inc.
• Minerva Surgical
• Olympus Corporation
   

Endometrial Ablation Devices Industry News

• In February 2023, KARL STORZ acquired 100 percent of the shares of AventaMed DAC, an Irish medical technologies company. This acquisition reflected KARL STORZ's commitment to innovation as it aimed to become the preferred partner of ENT surgeons for their cutting-edge endoscopic treatment missions.